Global Beraprost

Beraprost Comprehensive Study by Type (20mcg, 40mcg, 60 mcg, 80 mcg, 120 mcg), Application (Long Term therapy, Buerger's disease, Arteriosclerosis, Obliterans), End User (Hospitals, Clinical trials, Research Sectors) Players and Region - Global Market Outlook to 2024

Beraprost Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Beraprost Market Overview:
Beraprost is a prostacyclin analog with following properties vasodilatory, antiplatelet, antiproliferative effects on vascular smooth muscle cells, and cytoprotective. It is stable, orally active and appears to be an effective agent in the treatment of patients with Buerger's disease and arteriosclerosis obliterans. For Treatment of pulmonary arterial hypertension, beraprost sodium has sent to FDA approval in the orphan designation. It has been studied for the treatment of pulmonary hypertension and for use in avoiding reperfusion injury. Beraprost is basically known as an pharmaceutical drug consumed in several Asian countries, including Japan and South Korea, as a vasodilator and antiplatelet agent. Some of the key players profiled in the study are Toray Industries (Japan), Kaken Pharmaceuticals (Japan), Sanofi (France), Asahi Kasei Pharma (Japan), Shin Poong (Korea), Shiono Kemikaru (Japan), Ohara Pharmaceutical Co (Japan), Pfizer (United States), Sawai Seiyaku (Japan) and Teva (Israel).

On the basis of geography, the market of Beraprost has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End User, the sub-segment i.e. Hospitals will boost the Beraprost market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Suggested In Many Intractable Diseases
  • Demanded In Pulmonary Arterial Pressure Diorders
  • Highly Consumption Due To Oral Activity With Standard Therapy

Market Trend
  • Growing Used In Peripheral Chronic Arterial Occlusive Disease

Restraints
  • Problems Like Headache, Flushing, Jaw Pain, Diarrhea, Leg Pain, And Nausea Are Seen
  • Overdose Or Excess Use Result In Severe Bleeding, Hypotension, And Shock

Opportunities
  • Clinical Trials And Different Studies Are Going On For More Applications
  • Demand is More For Avoiding Reperfusion Injury

Challenges
  • Approval Of The FDA is Still Pending For Orphan Beraprost Sodium


Major Market Developments:

On November 25, 2019, Asahi Kasei Pharma Acquired Veloxis Pharmaceuticals Inc. to Accelerate Transformation into a Global Health Care Company. Asahi Kasei Corp decided that Asahi Kasei’s Danish subsidiary will indirectly acquire U.S. pharmaceutical company Veloxis Pharmaceuticals Inc, through a voluntary tender offer for Veloxis Pharmaceuticals, Denmark.
On January 29, 2020, Toray Industries, Inc, announced that it has created PICASUS VT, the world’s first film incorporating an optical function to allow light to pass through the front like glass and reflect obliquely incident light like a mirror. This revolutionary material opens new doors to applications in such areas as augmented and mixed reality for Head-Mounted Display (HMD) and Head-Up Display (HUD), and privacy filter and display films.
FDA has not granted approval to Beraprost sodium in orphan drug designation while orphan drugs are a category of synthetic pharmaceutical which remains commercially undeveloped. Beraprost sodium was the first chemically stable and orally active. As a result, beraprost did not get FDA approval.
Different Diseases are rising day by day, the beraprost has wide applications while clinical trials are going on to explore more uses of the beraprost drug. Japan has the main manufacturing companies of beraprost while other companies also trying to launch their products to take the market. There is a rivalry between leading companies as they are merging and acquiring with different firms.

Target Audience:
Manufacturers, Hospital and diagnostic centers, Distributors/Suppliers/Wholesalers, Government sector, Research firms, Industry Associate and Downstream Vendors

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Beraprost market on the basis of product [20mcg, 40mcg, 60 mcg, 80 mcg and 120 mcg] , application [Long Term therapy, Buerger's disease, Arteriosclerosis and Obliterans], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Beraprost market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Beraprost industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Towa Yakuhin (Japan), Yoshindo (Japan), Astellas (Japan) and Kaken Seiyaku (Japan).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Beraprost market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.

Report Objectives / Segmentation Covered

By Type
  • 20mcg
  • 40mcg
  • 60 mcg
  • 80 mcg
  • 120 mcg
By Application
  • Long Term therapy
  • Buerger's disease
  • Arteriosclerosis
  • Obliterans
By End User
  • Hospitals
  • Clinical trials
  • Research Sectors

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Suggested In Many Intractable Diseases
      • 3.2.2. Demanded In Pulmonary Arterial Pressure Diorders
      • 3.2.3. Highly Consumption Due To Oral Activity With Standard Therapy
    • 3.3. Market Challenges
      • 3.3.1. Approval Of The FDA is Still Pending For Orphan Beraprost Sodium
    • 3.4. Market Trends
      • 3.4.1. Growing Used In Peripheral Chronic Arterial Occlusive Disease
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Beraprost, by Type, Application, End User and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Beraprost (Value)
      • 5.2.1. Global Beraprost by: Type (Value)
        • 5.2.1.1. 20mcg
        • 5.2.1.2. 40mcg
        • 5.2.1.3. 60 mcg
        • 5.2.1.4. 80 mcg
        • 5.2.1.5. 120 mcg
      • 5.2.2. Global Beraprost by: Application (Value)
        • 5.2.2.1. Long Term therapy
        • 5.2.2.2. Buerger's disease
        • 5.2.2.3. Arteriosclerosis
        • 5.2.2.4. Obliterans
      • 5.2.3. Global Beraprost by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinical trials
        • 5.2.3.3. Research Sectors
      • 5.2.4. Global Beraprost Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Beraprost: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Toray Industries (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Kaken Pharmaceuticals (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Asahi Kasei Pharma (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Shin Poong (Korea)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Shiono Kemikaru (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Ohara Pharmaceutical Co (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sawai Seiyaku (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Teva (Israel)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Beraprost Sale, by Type, Application, End User and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Beraprost (Value)
      • 7.2.1. Global Beraprost by: Type (Value)
        • 7.2.1.1. 20mcg
        • 7.2.1.2. 40mcg
        • 7.2.1.3. 60 mcg
        • 7.2.1.4. 80 mcg
        • 7.2.1.5. 120 mcg
      • 7.2.2. Global Beraprost by: Application (Value)
        • 7.2.2.1. Long Term therapy
        • 7.2.2.2. Buerger's disease
        • 7.2.2.3. Arteriosclerosis
        • 7.2.2.4. Obliterans
      • 7.2.3. Global Beraprost by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinical trials
        • 7.2.3.3. Research Sectors
      • 7.2.4. Global Beraprost Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Beraprost: by Type(USD Million)
  • Table 2. Beraprost 20mcg , by Region USD Million (2013-2018)
  • Table 3. Beraprost 40mcg , by Region USD Million (2013-2018)
  • Table 4. Beraprost 60 mcg , by Region USD Million (2013-2018)
  • Table 5. Beraprost 80 mcg , by Region USD Million (2013-2018)
  • Table 6. Beraprost 120 mcg , by Region USD Million (2013-2018)
  • Table 7. Beraprost: by Application(USD Million)
  • Table 8. Beraprost Long Term therapy , by Region USD Million (2013-2018)
  • Table 9. Beraprost Buerger's disease , by Region USD Million (2013-2018)
  • Table 10. Beraprost Arteriosclerosis , by Region USD Million (2013-2018)
  • Table 11. Beraprost Obliterans , by Region USD Million (2013-2018)
  • Table 12. Beraprost: by End User(USD Million)
  • Table 13. Beraprost Hospitals , by Region USD Million (2013-2018)
  • Table 14. Beraprost Clinical trials , by Region USD Million (2013-2018)
  • Table 15. Beraprost Research Sectors , by Region USD Million (2013-2018)
  • Table 16. South America Beraprost, by Country USD Million (2013-2018)
  • Table 17. South America Beraprost, by Type USD Million (2013-2018)
  • Table 18. South America Beraprost, by Application USD Million (2013-2018)
  • Table 19. South America Beraprost, by End User USD Million (2013-2018)
  • Table 20. Brazil Beraprost, by Type USD Million (2013-2018)
  • Table 21. Brazil Beraprost, by Application USD Million (2013-2018)
  • Table 22. Brazil Beraprost, by End User USD Million (2013-2018)
  • Table 23. Argentina Beraprost, by Type USD Million (2013-2018)
  • Table 24. Argentina Beraprost, by Application USD Million (2013-2018)
  • Table 25. Argentina Beraprost, by End User USD Million (2013-2018)
  • Table 26. Rest of South America Beraprost, by Type USD Million (2013-2018)
  • Table 27. Rest of South America Beraprost, by Application USD Million (2013-2018)
  • Table 28. Rest of South America Beraprost, by End User USD Million (2013-2018)
  • Table 29. Asia Pacific Beraprost, by Country USD Million (2013-2018)
  • Table 30. Asia Pacific Beraprost, by Type USD Million (2013-2018)
  • Table 31. Asia Pacific Beraprost, by Application USD Million (2013-2018)
  • Table 32. Asia Pacific Beraprost, by End User USD Million (2013-2018)
  • Table 33. China Beraprost, by Type USD Million (2013-2018)
  • Table 34. China Beraprost, by Application USD Million (2013-2018)
  • Table 35. China Beraprost, by End User USD Million (2013-2018)
  • Table 36. Japan Beraprost, by Type USD Million (2013-2018)
  • Table 37. Japan Beraprost, by Application USD Million (2013-2018)
  • Table 38. Japan Beraprost, by End User USD Million (2013-2018)
  • Table 39. India Beraprost, by Type USD Million (2013-2018)
  • Table 40. India Beraprost, by Application USD Million (2013-2018)
  • Table 41. India Beraprost, by End User USD Million (2013-2018)
  • Table 42. South Korea Beraprost, by Type USD Million (2013-2018)
  • Table 43. South Korea Beraprost, by Application USD Million (2013-2018)
  • Table 44. South Korea Beraprost, by End User USD Million (2013-2018)
  • Table 45. Taiwan Beraprost, by Type USD Million (2013-2018)
  • Table 46. Taiwan Beraprost, by Application USD Million (2013-2018)
  • Table 47. Taiwan Beraprost, by End User USD Million (2013-2018)
  • Table 48. Australia Beraprost, by Type USD Million (2013-2018)
  • Table 49. Australia Beraprost, by Application USD Million (2013-2018)
  • Table 50. Australia Beraprost, by End User USD Million (2013-2018)
  • Table 51. Rest of Asia-Pacific Beraprost, by Type USD Million (2013-2018)
  • Table 52. Rest of Asia-Pacific Beraprost, by Application USD Million (2013-2018)
  • Table 53. Rest of Asia-Pacific Beraprost, by End User USD Million (2013-2018)
  • Table 54. Europe Beraprost, by Country USD Million (2013-2018)
  • Table 55. Europe Beraprost, by Type USD Million (2013-2018)
  • Table 56. Europe Beraprost, by Application USD Million (2013-2018)
  • Table 57. Europe Beraprost, by End User USD Million (2013-2018)
  • Table 58. Germany Beraprost, by Type USD Million (2013-2018)
  • Table 59. Germany Beraprost, by Application USD Million (2013-2018)
  • Table 60. Germany Beraprost, by End User USD Million (2013-2018)
  • Table 61. France Beraprost, by Type USD Million (2013-2018)
  • Table 62. France Beraprost, by Application USD Million (2013-2018)
  • Table 63. France Beraprost, by End User USD Million (2013-2018)
  • Table 64. Italy Beraprost, by Type USD Million (2013-2018)
  • Table 65. Italy Beraprost, by Application USD Million (2013-2018)
  • Table 66. Italy Beraprost, by End User USD Million (2013-2018)
  • Table 67. United Kingdom Beraprost, by Type USD Million (2013-2018)
  • Table 68. United Kingdom Beraprost, by Application USD Million (2013-2018)
  • Table 69. United Kingdom Beraprost, by End User USD Million (2013-2018)
  • Table 70. Netherlands Beraprost, by Type USD Million (2013-2018)
  • Table 71. Netherlands Beraprost, by Application USD Million (2013-2018)
  • Table 72. Netherlands Beraprost, by End User USD Million (2013-2018)
  • Table 73. Rest of Europe Beraprost, by Type USD Million (2013-2018)
  • Table 74. Rest of Europe Beraprost, by Application USD Million (2013-2018)
  • Table 75. Rest of Europe Beraprost, by End User USD Million (2013-2018)
  • Table 76. MEA Beraprost, by Country USD Million (2013-2018)
  • Table 77. MEA Beraprost, by Type USD Million (2013-2018)
  • Table 78. MEA Beraprost, by Application USD Million (2013-2018)
  • Table 79. MEA Beraprost, by End User USD Million (2013-2018)
  • Table 80. Middle East Beraprost, by Type USD Million (2013-2018)
  • Table 81. Middle East Beraprost, by Application USD Million (2013-2018)
  • Table 82. Middle East Beraprost, by End User USD Million (2013-2018)
  • Table 83. Africa Beraprost, by Type USD Million (2013-2018)
  • Table 84. Africa Beraprost, by Application USD Million (2013-2018)
  • Table 85. Africa Beraprost, by End User USD Million (2013-2018)
  • Table 86. North America Beraprost, by Country USD Million (2013-2018)
  • Table 87. North America Beraprost, by Type USD Million (2013-2018)
  • Table 88. North America Beraprost, by Application USD Million (2013-2018)
  • Table 89. North America Beraprost, by End User USD Million (2013-2018)
  • Table 90. United States Beraprost, by Type USD Million (2013-2018)
  • Table 91. United States Beraprost, by Application USD Million (2013-2018)
  • Table 92. United States Beraprost, by End User USD Million (2013-2018)
  • Table 93. Canada Beraprost, by Type USD Million (2013-2018)
  • Table 94. Canada Beraprost, by Application USD Million (2013-2018)
  • Table 95. Canada Beraprost, by End User USD Million (2013-2018)
  • Table 96. Mexico Beraprost, by Type USD Million (2013-2018)
  • Table 97. Mexico Beraprost, by Application USD Million (2013-2018)
  • Table 98. Mexico Beraprost, by End User USD Million (2013-2018)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Beraprost: by Type(USD Million)
  • Table 110. Beraprost 20mcg , by Region USD Million (2019-2024)
  • Table 111. Beraprost 40mcg , by Region USD Million (2019-2024)
  • Table 112. Beraprost 60 mcg , by Region USD Million (2019-2024)
  • Table 113. Beraprost 80 mcg , by Region USD Million (2019-2024)
  • Table 114. Beraprost 120 mcg , by Region USD Million (2019-2024)
  • Table 115. Beraprost: by Application(USD Million)
  • Table 116. Beraprost Long Term therapy , by Region USD Million (2019-2024)
  • Table 117. Beraprost Buerger's disease , by Region USD Million (2019-2024)
  • Table 118. Beraprost Arteriosclerosis , by Region USD Million (2019-2024)
  • Table 119. Beraprost Obliterans , by Region USD Million (2019-2024)
  • Table 120. Beraprost: by End User(USD Million)
  • Table 121. Beraprost Hospitals , by Region USD Million (2019-2024)
  • Table 122. Beraprost Clinical trials , by Region USD Million (2019-2024)
  • Table 123. Beraprost Research Sectors , by Region USD Million (2019-2024)
  • Table 124. South America Beraprost, by Country USD Million (2019-2024)
  • Table 125. South America Beraprost, by Type USD Million (2019-2024)
  • Table 126. South America Beraprost, by Application USD Million (2019-2024)
  • Table 127. South America Beraprost, by End User USD Million (2019-2024)
  • Table 128. Brazil Beraprost, by Type USD Million (2019-2024)
  • Table 129. Brazil Beraprost, by Application USD Million (2019-2024)
  • Table 130. Brazil Beraprost, by End User USD Million (2019-2024)
  • Table 131. Argentina Beraprost, by Type USD Million (2019-2024)
  • Table 132. Argentina Beraprost, by Application USD Million (2019-2024)
  • Table 133. Argentina Beraprost, by End User USD Million (2019-2024)
  • Table 134. Rest of South America Beraprost, by Type USD Million (2019-2024)
  • Table 135. Rest of South America Beraprost, by Application USD Million (2019-2024)
  • Table 136. Rest of South America Beraprost, by End User USD Million (2019-2024)
  • Table 137. Asia Pacific Beraprost, by Country USD Million (2019-2024)
  • Table 138. Asia Pacific Beraprost, by Type USD Million (2019-2024)
  • Table 139. Asia Pacific Beraprost, by Application USD Million (2019-2024)
  • Table 140. Asia Pacific Beraprost, by End User USD Million (2019-2024)
  • Table 141. China Beraprost, by Type USD Million (2019-2024)
  • Table 142. China Beraprost, by Application USD Million (2019-2024)
  • Table 143. China Beraprost, by End User USD Million (2019-2024)
  • Table 144. Japan Beraprost, by Type USD Million (2019-2024)
  • Table 145. Japan Beraprost, by Application USD Million (2019-2024)
  • Table 146. Japan Beraprost, by End User USD Million (2019-2024)
  • Table 147. India Beraprost, by Type USD Million (2019-2024)
  • Table 148. India Beraprost, by Application USD Million (2019-2024)
  • Table 149. India Beraprost, by End User USD Million (2019-2024)
  • Table 150. South Korea Beraprost, by Type USD Million (2019-2024)
  • Table 151. South Korea Beraprost, by Application USD Million (2019-2024)
  • Table 152. South Korea Beraprost, by End User USD Million (2019-2024)
  • Table 153. Taiwan Beraprost, by Type USD Million (2019-2024)
  • Table 154. Taiwan Beraprost, by Application USD Million (2019-2024)
  • Table 155. Taiwan Beraprost, by End User USD Million (2019-2024)
  • Table 156. Australia Beraprost, by Type USD Million (2019-2024)
  • Table 157. Australia Beraprost, by Application USD Million (2019-2024)
  • Table 158. Australia Beraprost, by End User USD Million (2019-2024)
  • Table 159. Rest of Asia-Pacific Beraprost, by Type USD Million (2019-2024)
  • Table 160. Rest of Asia-Pacific Beraprost, by Application USD Million (2019-2024)
  • Table 161. Rest of Asia-Pacific Beraprost, by End User USD Million (2019-2024)
  • Table 162. Europe Beraprost, by Country USD Million (2019-2024)
  • Table 163. Europe Beraprost, by Type USD Million (2019-2024)
  • Table 164. Europe Beraprost, by Application USD Million (2019-2024)
  • Table 165. Europe Beraprost, by End User USD Million (2019-2024)
  • Table 166. Germany Beraprost, by Type USD Million (2019-2024)
  • Table 167. Germany Beraprost, by Application USD Million (2019-2024)
  • Table 168. Germany Beraprost, by End User USD Million (2019-2024)
  • Table 169. France Beraprost, by Type USD Million (2019-2024)
  • Table 170. France Beraprost, by Application USD Million (2019-2024)
  • Table 171. France Beraprost, by End User USD Million (2019-2024)
  • Table 172. Italy Beraprost, by Type USD Million (2019-2024)
  • Table 173. Italy Beraprost, by Application USD Million (2019-2024)
  • Table 174. Italy Beraprost, by End User USD Million (2019-2024)
  • Table 175. United Kingdom Beraprost, by Type USD Million (2019-2024)
  • Table 176. United Kingdom Beraprost, by Application USD Million (2019-2024)
  • Table 177. United Kingdom Beraprost, by End User USD Million (2019-2024)
  • Table 178. Netherlands Beraprost, by Type USD Million (2019-2024)
  • Table 179. Netherlands Beraprost, by Application USD Million (2019-2024)
  • Table 180. Netherlands Beraprost, by End User USD Million (2019-2024)
  • Table 181. Rest of Europe Beraprost, by Type USD Million (2019-2024)
  • Table 182. Rest of Europe Beraprost, by Application USD Million (2019-2024)
  • Table 183. Rest of Europe Beraprost, by End User USD Million (2019-2024)
  • Table 184. MEA Beraprost, by Country USD Million (2019-2024)
  • Table 185. MEA Beraprost, by Type USD Million (2019-2024)
  • Table 186. MEA Beraprost, by Application USD Million (2019-2024)
  • Table 187. MEA Beraprost, by End User USD Million (2019-2024)
  • Table 188. Middle East Beraprost, by Type USD Million (2019-2024)
  • Table 189. Middle East Beraprost, by Application USD Million (2019-2024)
  • Table 190. Middle East Beraprost, by End User USD Million (2019-2024)
  • Table 191. Africa Beraprost, by Type USD Million (2019-2024)
  • Table 192. Africa Beraprost, by Application USD Million (2019-2024)
  • Table 193. Africa Beraprost, by End User USD Million (2019-2024)
  • Table 194. North America Beraprost, by Country USD Million (2019-2024)
  • Table 195. North America Beraprost, by Type USD Million (2019-2024)
  • Table 196. North America Beraprost, by Application USD Million (2019-2024)
  • Table 197. North America Beraprost, by End User USD Million (2019-2024)
  • Table 198. United States Beraprost, by Type USD Million (2019-2024)
  • Table 199. United States Beraprost, by Application USD Million (2019-2024)
  • Table 200. United States Beraprost, by End User USD Million (2019-2024)
  • Table 201. Canada Beraprost, by Type USD Million (2019-2024)
  • Table 202. Canada Beraprost, by Application USD Million (2019-2024)
  • Table 203. Canada Beraprost, by End User USD Million (2019-2024)
  • Table 204. Mexico Beraprost, by Type USD Million (2019-2024)
  • Table 205. Mexico Beraprost, by Application USD Million (2019-2024)
  • Table 206. Mexico Beraprost, by End User USD Million (2019-2024)
  • Table 207. Research Programs/Design for This Report
  • Table 208. Key Data Information from Secondary Sources
  • Table 209. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Beraprost: by Type USD Million (2013-2018)
  • Figure 5. Global Beraprost: by Application USD Million (2013-2018)
  • Figure 6. Global Beraprost: by End User USD Million (2013-2018)
  • Figure 7. South America Beraprost Share (%), by Country
  • Figure 8. Asia Pacific Beraprost Share (%), by Country
  • Figure 9. Europe Beraprost Share (%), by Country
  • Figure 10. MEA Beraprost Share (%), by Country
  • Figure 11. North America Beraprost Share (%), by Country
  • Figure 12. Global Beraprost share by Players 2018 (%)
  • Figure 13. Global Beraprost share by Players (Top 3) 2018(%)
  • Figure 14. Global Beraprost share by Players (Top 5) 2018(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Toray Industries (Japan) Revenue, Net Income and Gross profit
  • Figure 17. Toray Industries (Japan) Revenue: by Geography 2018
  • Figure 18. Kaken Pharmaceuticals (Japan) Revenue, Net Income and Gross profit
  • Figure 19. Kaken Pharmaceuticals (Japan) Revenue: by Geography 2018
  • Figure 20. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 21. Sanofi (France) Revenue: by Geography 2018
  • Figure 22. Asahi Kasei Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 23. Asahi Kasei Pharma (Japan) Revenue: by Geography 2018
  • Figure 24. Shin Poong (Korea) Revenue, Net Income and Gross profit
  • Figure 25. Shin Poong (Korea) Revenue: by Geography 2018
  • Figure 26. Shiono Kemikaru (Japan) Revenue, Net Income and Gross profit
  • Figure 27. Shiono Kemikaru (Japan) Revenue: by Geography 2018
  • Figure 28. Ohara Pharmaceutical Co (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Ohara Pharmaceutical Co (Japan) Revenue: by Geography 2018
  • Figure 30. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer (United States) Revenue: by Geography 2018
  • Figure 32. Sawai Seiyaku (Japan) Revenue, Net Income and Gross profit
  • Figure 33. Sawai Seiyaku (Japan) Revenue: by Geography 2018
  • Figure 34. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 35. Teva (Israel) Revenue: by Geography 2018
  • Figure 36. Global Beraprost: by Type USD Million (2019-2024)
  • Figure 37. Global Beraprost: by Application USD Million (2019-2024)
  • Figure 38. Global Beraprost: by End User USD Million (2019-2024)
  • Figure 39. South America Beraprost Share (%), by Country
  • Figure 40. Asia Pacific Beraprost Share (%), by Country
  • Figure 41. Europe Beraprost Share (%), by Country
  • Figure 42. MEA Beraprost Share (%), by Country
  • Figure 43. North America Beraprost Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Toray Industries (Japan)
  • Kaken Pharmaceuticals (Japan)
  • Sanofi (France)
  • Asahi Kasei Pharma (Japan)
  • Shin Poong (Korea)
  • Shiono Kemikaru (Japan)
  • Ohara Pharmaceutical Co (Japan)
  • Pfizer (United States)
  • Sawai Seiyaku (Japan)
  • Teva (Israel)
Additional players considered in the study are as follows:
Towa Yakuhin (Japan) , Yoshindo (Japan) , Astellas (Japan) , Kaken Seiyaku (Japan)
Select User Access Type

Key Highlights of Report


Mar 2020 207 Pages 63 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Beraprost Quantitative research analysis
Global Beraprost Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Beraprost Report?

Have a Query? Click Here

Other Related Reports

Antidepressant Drugs Comprehensive Study by Type (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder), Application (Depression, Generalized anxiety...
$ 3750
Pneumococcal Vaccine Comprehensive Study by Type (Conjugate Vaccines (PCV13), Polysaccharide Vaccines (PPSV23)), Application (Medical care, Clinics, Hospitals, Others), Sector Type (Public, Private),...
$ 3750
Irinotecan Comprehensive Study by Type (Irinotecan Hydrochloride Injection 40mg, Irinotecan Hydrochloride Injection 100mg, Other), Application (Colon cancer, Rectal cancer), Route of Administration (...
$ 3500
Tobramycin Eye Drop Comprehensive Study by Type (Tobramycin and dexamethasone ophthalmic suspension, Tobramycin ophthalmic suspension, Other tobramycin Combination), Application (Adult, Children), En...
$ 3650
Policresulen Comprehensive Study by Type (Gels, Suppositories, Lotion, Implants, Soft Cream, Injection, Tablets, Capsule, Other), Application (Department Of Gynaecology, Surgery And Dermatology, Kouq...
$ 3650
mRNA Cancer Vaccines and Therapeutics Comprehensive Study by Type (Adeno Carcinomas, Mucinous Carcinomas, Adenosquamous Carcinomas), Application (Infectious Disease, Cancer, Others), End-users (Hospi...
$ 3500